Age accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Park, Min Sun ^a   Lee, Hi Bahl ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Advanced glycosylation end products; High glucose; Peritoneal fibrosis; Peritoneal membrane function

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIALYSIS FLUID; GLUCOSE; PENTOSIDINE;

BASEMENT MEMBRANE; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; FLUID BALANCE; HUMAN; HYPERGLYCEMIA; MEMBRANE PERMEABILITY; OXIDATIVE STRESS; PERITONEAL CAVITY; PRIORITY JOURNAL; ULTRAFILTRATION; UREMIA;

EID: 0033395799     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s09     Document Type: Conference Paper

References (45)

1. Nathan DM, Singer DE, Godine JE, Harrington CH, Perluter LC. Retinopathy in older type II diabetics: Association with glucose control. Diabetes. 1986; 35:797-801.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:979-86.
3. Brownlee M, Vlassara H, Cerami M. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1993; 101:527-37.
4. Vlassara H. Serum advanced glycosylation end products: A new class of uremic toxin? Blood Purif. 1994; 12:54-9.
5. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic nephropathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984; 102:527-32.
6. Friedlander MA, Wu YC, Elgawish A, Monnier VM. Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis. J Clin Invest. 1996; 97:728-35.
7. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y. Clearance of pentosidine, an advanced glycosylation end product, by different modalities of renal replacement therapy. Kidney Int. 1997; 51:880-7.
8. Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakao H, Nozaki O, et al. Immunohistochemical study of human advanced glycosylation end-products (AGEs) in chronic renal failure. Clin Nephrol. 1994; 42:354-61.
9. Nakayama M, Kubo H, Ogawa A, Yamamoto Y, Kato N, Hayakawa H, et al. Immunohistochemical detection of advanced glycation end products (AGEs) in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997; 51:182-6.
10. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci U S A. 1992; 89:12043-7.
11. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318:1315-21.
12. Heimbürger O, Waniewski J, Werynski A, Lindholm B. A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int. 1992; 41:1320-32.
13. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull. 1987; 7:138-47.
14. Heimbürger O, Waniewski J, Werynski A, Tranæus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int. 1990; 38:495-506.
15. Lindholm B, Bergström B. Nutritional management of patients undergoing peritoneal dialysis. In: Nolph KD, ed. Peritoneal Dialysis. Dordrecht: Kluwer Academic Publishers, 1987:230-60.
16. Breborowicz A, Balaskas E, Oreopoulos GD, Martis L, Serkes K, Oreopoulos DG. In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity. Perit Dial Int. 1994; 14:149-54.
17. Topley N, Coles GA, Williams JD. Biocompatibility studies on peritoneal cells. Perit Dial Int. 1994; 14(Suppl 3):S21-8.
18. Breborowicz A, Rodela H, Karon J, Martis L, Oreopoulos DG. In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells. Am J Kidney Dis. 1997; 29:404-9.
19. Ha H, Yu MR, Park MS, Lee HB. High glucose-induced TGF-β1 and fibronectin synthesis by human peritoneal mesothelial cell: Involvement of PKC [Abstract]. Perit Dial Int. 1998; 18:111.
20. Dobbie JW. Morphology of the peritoneum in CAPD. Blood Purif. 1989; 7:74-85.
21. Dobbie JW. Monitoring of peritoneal histopathology in peritoneal dialysis: The role of a biopsy registry. Nephrol Dial Transplant. 1989; 18:319-35.
22. Kilzer P, Chang K, Marvel J, Rowold E, Jaudes P, Ullensvang S, et al. Albumin permeation of new vessels is increased in diabetic rats. Diabetes. 1985; 34: 333-6.
23. Lee HB, Park MS, Han DC. Hwang SD. Stability of peritoneal solute and water transfer. Korean J Nephrol. 1991; 10:87-16.
24. Lee HB, Park MS, Chung SH, So IN, Han DC, Lee SK, et al. Peritoneal membrane performance after 5 years of CAPD. In: Current Concepts in Peritoneal Dialysis. Kyoto: Elsevier Science Publishers; 1992: 84-8.
25. Selgas R, Bajo MA, Paiva A, DelPaso G, Diaz C, Arguelera A, et al. Stability of the peritoneal membrane in long-term peritoneal dialysis patients. Adv Ren Replace Ther. 1998; 5:168-78.
26. Krediet RT. Prevention and treatment of peritoneal dialysis membrane failure. Adv Ren Replace Ther. 1998; 5:212-17.
27. Monquil MC, Imholz AL, Struijk DG, Krediet RT. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int. 1995; 15:42-8.
28. Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glycosylation and glucose-dependent cross-linking of protein. J Biol Chem. 1983; 258:9406-12.
29. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunie M, Verger C, et al. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol. 1996; 45:379-82.
30. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW. Serum advanced glycosylation end-products in patients on hemodialysis and CAPD. Perit Dial Int. 1995; 15:129-33.
31. Maihout A, Ehlerding G, Brunkhorst R. Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant. 1996; 11(Suppl 5):2-6.
32. Lamb E, Cattell WR, Dawnay A. Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci. 1993; 84:619-26.
33. Miyata T, Wada Y, Cal Z, Horie K, Yasuda Y, Maeda K, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end stage renal failure. Kidney Int. 1997; 51:1170-81.
34. Weiss MF. Pathogenic role of advanced glycation end-products (AGEs): An overview. Pent Dial Int. 1999; 19(Suppl 2):S47-52.
35. Miyata T, Izuhara Y, Sakai H, Kurokawa K. Carbonyl stress: Increased carbonyl modification of tissue and cellular proteins in uremia. Perit Dial Int. 1999; 19(Suppl 2):S58-61.
36. Ho-dac-Pannekeet MM, Weiss MF, de Waart DR, Erhard P, Hiralall JK, Krediet RT. Analysis of non enzymatic glycosylation in vivo: Impact of different dialysis solutions. Perit Dial Int. 1999; 19(Suppl 2): S68-74.
37. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984; 101:527-37.
38. Dobbie JW, Anderson JD, Hind C. Long-term effect of peritoneal dialysis on peritoneal morphology. Perit Dial Int. 1994; 14:816-20.
39. Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis. Am J Kidney Dis. 1990; 15:97-109.
40. Gotloib L, Bar-Sella P, Shostak A. Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: Ultrastructural changes of reduplicated peritoneal basement membrane. Perit Dial Bull. 1985; 5:212-15.
41. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vitro model for the study of diabetic microangiopathy. Perit Dial Int. 1989; 9:41-5.
42. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science. 1986; 232:1629-32.
43. Park MS. Factors increasing severity of peritonitis in long-term peritoneal dialysis patients. Adv Ren Replace Ther. 1998; 5:185-93.
44. Weiss MF, Saxena AK, Monnier VM. Pharmacological modulation of AGEs: A unique role for redox-active metal ions. Perit Dial Int. 1999; 19(Suppl 2)S62-67.
45. Wieslander A, Deppisch R, Svensson E, Forsback G. In vitro biocompatibility of a heat sterilized, low toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int. 1995; 15:158-64.